IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears
IGC Pharma received Canadian Patent No. 3,095,729 covering the composition of IGC-AD1, its investigational oral therapy for agitation in Alzheimer's. With this grant, IGC-AD1 is now patented in all three North American markets and protected by 5 granted patents, with 10 applications pending worldwide. The more significant near-term catalyst is the CALMA Phase 2 trial, which completed enrollment in September 2026 and is in its final dosing period, with topline results to follow database lock and unblinding.
Key figures
- Drug Name
- IGC-AD1
- Phase Of Trial
- Phase 2
- Us patent no
- 12,465,589
- Granted patents
- 5
- Mexican patent no
- 409,414
- Canadian patent no
- 3,095,729
- Pending applications
- 10
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.